Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
04/25/2023 - 08:30 AM
CAMBRIDGE, Mass. --(BUSINESS WIRE)--
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2023 financial results after the Nasdaq Global Market closes on Tuesday, May 2, 2023 . Subsequently, at 4:30 p.m. E.T. , the Company will host a conference call to discuss its first quarter 2023 financial results.
The event will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations this online form
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter , LinkedIn , Instagram and Facebook .
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com . We encourage investors and potential investors to consult our website regularly for important information about us.
View source version on businesswire.com : https://www.businesswire.com/news/home/20230425005062/en/
Investor:
Ian Estepan , 617-274-4052
iestepan@sarepta.com
Media:
Tracy Sorrentino , 617-301-8566
tsorrentino@sarepta.com
Source: Sarepta Therapeutics, Inc.
SRPT Rankings
#2404 Ranked by Stock Gains
SRPT Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
Cambridge
About SRPT
sarepta therapeutics is a biopharmaceutical company focused on the discovery and development of unique rna-targeted therapeutics for the treatment of rare, infectious and other diseases. the company is primarily focused on rapidly advancing the development of its potentially disease-modifying dmd drug candidates, including its lead dmd product candidate, eteplirsen, designed to skip exon 51. sarepta is also developing therapeutics for the treatment of infectious diseases, such as drug-resistant bacteria and other rare human diseases. for more information, please visit us at www.sarepta.com.
